Xuewu Liang

机构：Chinese Academy of Sciences, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences · ORCID：0000-0002-6931-9242

发表论文 53 篇 · 总被引 981 次 · h-index 16

代表论文

• MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies (2021 · Medicinal Research Reviews · 被引 32)
• Identification and experimental validation of PYCARD as a crucial PANoptosis-related gene for immune response and inflammation in COPD (2024 · APOPTOSIS · 被引 31)
• Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies (2024 · Journal of Medicinal Chemistry · 被引 25)
• The new direction of drug development: Degradation of undruggable targets through targeting chimera technology (2023 · Medicinal Research Reviews · 被引 24)
• Discovery of Novel Imidazo[4,5- c ]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis (2022 · Journal of Medicinal Chemistry · 被引 23)
• Discovery of Novel RNA Demethylase FTO Inhibitors Featuring an Acylhydrazone Scaffold with Potent Antileukemia Activity (2025 · Journal of Medicinal Chemistry · 被引 17)